Time Restricted Eating for WeIght LoSs MainTenance-2

NCT ID: NCT07190170

Last Updated: 2025-12-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

110 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-10-01

Study Completion Date

2028-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The TWIST 2.0 Study is a 12-month, 2-arm RCT in adults with recent weight loss. We will examine the efficacy of TRE on weight (Aim 1a) and fat mass (Aim 1b) regain, and describe changes in subjective appetite following a mixed-meal tolerance test (Exploratory).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The TWIST 2.0 Study is a 12-month, 2-arm RCT in adults with recent weight loss. We will examine the efficacy of TRE on weight (Aim 1a) and fat mass (Aim 1b) regain, and describe changes in subjective appetite following a mixed-meal tolerance test (Exploratory). Potential participants will be screened via telephone and eligible participants will attend an in-person screening visit where they will complete questionnaires and have their height and weight measured. We will perform a 4-week run-in period to establish weight stabilization and measure eating patterns before randomization. Eligible participants following the run-in period will be randomized with equal allocation to one of the 2 arms: 1) TRE intervention ≤10-hr/day TRE intervention); or 2) CON. At baseline, 6 and 12 month measurements, participants will complete a bioelectrical impedance analysis (BIA) and dual energy x-ray absorptiometry (DEXA) scan by a certified radiology technician. Within each arm, participants will be randomized to either complete or not complete a mixed meal tolerance test in which they will consume a small portion of a protein shake and complete a visual analog scale (VAS) on their subjective hunger/fullness. Participants in both arms will receive one-page handouts (i.e., "advice") on topics to assist with weight maintenance. The only between-group differences are the TRE arm will be instructed to follow a restricted eating window of ≤10 hr/day, self-monitor foods and beverages into a smartphone app, measure body weight using a Bluetooth-enabled scale, and receive behavioral counseling directed at sustaining adherence to the TRE intervention. The CON arm will be unrestricted in their eating window and encouraged to eat a habitual breakfast, lunch, and dinner. No additional contact will be made between the CON arm and interventionist during the 12 months unless we schedule a measurement visit. Digital newsletters will be provided every month for the first 6 mos, and then every other month containing complementary information on WLM to engage participants in the CON arm. The same newsletters will be going to the TRE.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Weight Loss Maintenance Weight Gain Weight Loss

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

obesity time-restricted eating weight-loss maintenance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Time-Restricted Eating (TRE)

Participants assigned to the intervention: ≤10-hour/day time restricted eating.

Group Type EXPERIMENTAL

TRE

Intervention Type BEHAVIORAL

Participants randomized to the TRE arm will be instructed to consume all food and beverages in a self-selected 10-hr eating window.

Baseline Advice Control (CON)

Participants assigned to receive baseline advice.

Group Type ACTIVE_COMPARATOR

Weight-Loss Maintenance Advice

Intervention Type BEHAVIORAL

The CON arm participants will receive written baseline advice following randomization assignment that includes determinants associated with long-term weight-loss maintenance success (e.g., physical activity, and strategies to limit calorie intake).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TRE

Participants randomized to the TRE arm will be instructed to consume all food and beverages in a self-selected 10-hr eating window.

Intervention Type BEHAVIORAL

Weight-Loss Maintenance Advice

The CON arm participants will receive written baseline advice following randomization assignment that includes determinants associated with long-term weight-loss maintenance success (e.g., physical activity, and strategies to limit calorie intake).

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ≥5% non-surgical weight loss in the last 3 mos;
* current BMI 20.5-45 mg/kg2;
* between the ages 25 to 65 years old;
* own a smartphone or willing to use a smartphone if provided for self-monitoring. For in-person screening, eligible participants will provide signed informed consent and have their temporal eating patterns measured.

Exclusion Criteria

* pregnant, trying to get pregnant or breastfeeding;
* previous or planned bariatric surgery;
* previous or current history of eating disorder;
* ongoing participation in another weight-management research study;
* continued participation in a weight loss program other than the proposed study;
* currently on appetite suppressants;
* currently following intermittent fasting; or skipping meals;
* eating window \<11h 59min/day;
* perform overnight shift work more than once a week;
* work that includes travel across one or more time zones;
* taking medications that affect body weight or would preclude TRE;
* unable or unwilling to provide informed consent;
* unable to participate meaningfully in the intervention (e.g., uncorrected sight and hearing impairment);
* unwilling to accept randomization assignment;
* unable to log at least 2 meals into the smartphone app for 70% (\~20 days) during of the run-in period;
* have type 1 or type 2 diabetes, or other conditions that would preclude restricted eating windows;
* narcolepsy,
* is non-English speaking (the mCC app is currently only available in English).
Minimum Eligible Age

25 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Heart, Lung, and Blood Institute (NHLBI)

NIH

Sponsor Role collaborator

NYU Langone Health

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Collin Popp

Role: PRINCIPAL_INVESTIGATOR

NYU Langone Health

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

NYU Langone Health

New York, New York, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Collin Popp

Role: CONTACT

Phone: 646-501-3427

Email: [email protected]

Margaret Curran

Role: CONTACT

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

4R00HL163474

Identifier Type: NIH

Identifier Source: secondary_id

View Link

25-00320

Identifier Type: -

Identifier Source: org_study_id